Abstract
Purpose of Review: Antidepressants are widely prescribed, but potentially persistent adverse effects, such as tardive dyskinesia, are increasingly recognized. The literature on antidepressant-induced tardive dyskinesia (AITD) remains largely based on case reports and small observational studies, with potential confounding by concomitant medications. This scoping review maps the available evidence on antidepressant-induced tardive dyskinesia, including its occurrence and clinical characteristics, and was conducted in accordance with the Joanna Briggs Institute methodology and reported following the PRISMA-ScR guidelines. A comprehensive search was conducted in PubMed (MEDLINE), PsycINFO, Cochrane Library, and Google Scholar. Two reviewers independently screened and reviewed included studies, achieving complete agreement throughout the selection process. Recent Findings: Thirty-nine reports were reviewed, including 31 case reports, 5 case series, 1 prospective prevalence study, 1 retrospective cross-sectional study, and 1 pharmacovigilance study. The most frequently reported drugs were selective serotonin reuptake inhibitors, with fluoxetine accounting for the largest number of published reports. Clinical latency ranged from less than 24 h to approximately 10 years of exposure, and the most frequent symptoms were orofacial and buccolingual dyskinesias. Observational evidence identified prevalence estimates of tardive dyskinesia ranging from 3.2% to 6%, while pharmacovigilance data demonstrated significant disproportionality signals for amoxapine and venlafaxine. Summary: Antidepressants may be associated with tardive dyskinesia, particularly serotonergic antidepressants. The current evidence remains insufficient to establish definitive causality or a clear comparative risk across antidepressant classes. Prospective cohort studies and pharmacovigilance registries are needed to better characterize the incidence, risk factors, mechanisms, and long-term outcomes of AITD.
| Original language | English |
|---|---|
| Article number | 22 |
| Number of pages | 28 |
| Journal | Current Treatment Options in Psychiatry |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Dec 2026 |
Keywords
- Antidepressants
- Drug-induced movement disorders
- Extrapyramidal symptoms
- Pharmacovigilance
- Selective serotonin reuptake inhibitors
- Tardive dyskinesia
Fingerprint
Dive into the research topics of 'Risk of antidepressant-induced tardive dyskinesia: a scoping review of evidence and high-risk agents'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver